What Analysts Are Saying About Bristol-Myers Squibb Stock
Portfolio Pulse from Benzinga Insights
Analysts have mixed opinions on Bristol-Myers Squibb (NYSE:BMY), with most ratings being indifferent. The average 12-month price target has slightly increased to $46.0. The company's financial performance shows strong net margins and asset utilization but lags in revenue growth compared to peers.
September 16, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed views on Bristol-Myers Squibb, with most ratings being indifferent. The average price target has slightly increased, indicating a modest positive sentiment. The company's strong net margins and asset utilization are positive, but revenue growth lags behind peers.
The article provides a detailed analysis of analyst ratings for BMY, showing a mix of indifferent and somewhat bearish sentiments. The slight increase in the average price target suggests a modest positive outlook. Financial metrics like strong net margins and asset utilization are positive, but the lag in revenue growth compared to peers is a concern.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100